ICP-248 in Combination with Orelabrutinib in Treatment-na√Øve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Evaluate the safety, tolerability and pharmacokinetics of ICP-248 in Combination with Orelabrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Hematologic Malignancies
DRUG: ICP-248|DRUG: Orelabrutinib
Adverse events (AEs) and serious adverse events (SAEs) evaluation according to CTCAE V5.0 or iwCLL 2018 criteria, Up to 6 years|Changes from baseline in pulse., Up to 6 years|Changes from baseline in blood pressure., Up to 6 years|Changes from baseline in ECG QRS interval., Up to 6 years|Changes from baseline in ECG QT interval., Up to 6 years
Evaluate the safety, tolerability and pharmacokinetics of ICP-248 in Combination with Orelabrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma